Oedema‐based model for diffuse low‐grade gliomas: application to clinical cases under radiotherapy. (19th June 2014)

• Record Type: Journal Article
• Authors: Badoual, M.; Gerin, C.; Deroulers, C.; Grammaticos, B.; Llitjos, J.‐F.; Oppenheim, C.; Varlet, P.; Pallud, J.
• Is Part Of: Cell proliferation. Volume 47:Number 4(2014:Aug.)
• Page Start: 369
• Page End: 380
• Publication Date: 2014-06-19
• Subjects: Cell proliferation -- Periodicals; 571.84
• DOI: 10.1111/cpr.12114
• Languages: English
• ISSNs: 0960-7722

Abstract

<abstract abstract-type="main" id="cpr12114-abs-0001"> <title>Abstract</title> <sec id="cpr12114-sec-0001" sec-type="section"> <title>Objectives</title> <p>Diffuse low‐grade gliomas are characterized by slow growth. Despite appropriate treatment, they change inexorably into more aggressive forms, jeopardizing the patient's life. Optimizing treatments, for example with the use of mathematical modelling, could help to prevent tumour regrowth and anaplastic transformation. Here, we present a model of the effect of radiotherapy on such tumours. Our objective is to explain observed delay of tumour regrowth following radiotherapy and to predict its duration.</p> </sec> <sec id="cpr12114-sec-0002" sec-type="section"> <title>Materials and methods</title> <p>We have used a migration–proliferation model complemented by an equation describing appearance and draining of oedema. The model has been applied to clinical data of tumour radius over time, for a population of 28 patients.</p> </sec> <sec id="cpr12114-sec-0003" sec-type="section"> <title>Results</title> <p>We were able to show that draining of oedema accounts for regrowth delay after radiotherapy and have been able to fit the clinical data in a robust way. The model predicts strong correlation between high proliferation coefficient and low progression‐free gain of lifetime, due to radiotherapy among the patients, in agreement with clinical studies.</p> <p>We argue that, with reasonable assumptions, it is possible to predict (precision ~20%) regrowth delay after radiotherapy and the gain of lifetime due to radiotherapy.</p> </sec> <sec id="cpr12114-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Our oedema‐based model provides an early estimation of individual duration of tumour response to radiotherapy and thus, opens the door to the possibility of personalized medicine.</p> </sec> </abstract>